SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Madharry who wrote (901)1/21/2002 5:30:36 PM
From: Elmer  Read Replies (2) of 3044
 
<i don't like it>
No argument here. My only point is that I agree with what the article says. MLNM is buying CORR so that it will have the scale to avoid being a target itself two years out.

Big Pharma will be looking for product based biotech stocks to acquire. MLNM is trying to get there first.

OT: Page 44 of the proxy solicitation in Morgan Stanley's fairness opinion lists five Mid-cap Product-Based Biotech Companies. They include GILD, CEPH, ENZN, CELG and QLTI. Each of these companies will also be looking to do acquisitions to avoid being bought out by big Pharma. A strategy I may use is to buy these stock after their prices decline on future acquisition announcements or alternatively just buy their targets and wait for the exchange.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News